Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer
about
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancerPredicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models.Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian womenBreast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec.Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in QuebecDescription and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases.Breast cancer risk-assessment models.Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.Establishing a program for individuals at high risk for breast cancer.Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutationAssessing women at high risk of breast cancer: a review of risk assessment models.Analysis of ZNF350/ZBRK1 promoter variants and breast cancer susceptibility in non-BRCA1/2 French Canadian breast cancer families.Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal.Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families.Cultural aspects of healthy BRCA carriers from two ethnocultural groups.Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility.Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent
P2860
Q33258847-2A3BA7BE-965F-4E69-BCF0-E105EB5B3830Q33327591-46A2BEBD-8C64-48DD-ADED-EB4E2489F7ADQ33360437-751247FD-F457-4FAB-9A58-3756A7C3B3DFQ33467074-9879F3CA-224C-4DF5-BA35-084BCCE870E8Q34102617-2A2B77F2-1934-4443-B636-A2860855539CQ34288968-73421AE6-4A8A-4F4B-BA5B-1D92C7CB50A3Q34720527-92028C9B-FADB-4B5D-81BF-46187FE7F4CDQ34873841-B3EC9D5E-B5C2-41B7-9F7C-667AF2C7084DQ34879739-484C8C38-F314-4B63-8058-E12FA14AB2A1Q35223166-4DEC0F80-E3A2-4F6A-B484-5873061EC429Q35444944-8052085D-CC7A-49A8-A712-1CDBA9676240Q35630889-B0390207-DA19-4DD4-AE9F-EC06B1A6CAB3Q36458723-D017788D-2085-40DE-83DA-4E7BD4BCD544Q36955087-8D2CFFF2-C266-49EC-B70F-7C7206927C8EQ36983389-1F77749F-AF41-4FF3-86DC-F29F7FC3BAF9Q37081117-4E66B9CE-79FE-404F-8723-83CBC2E2EB0AQ37739036-EE576D19-1658-4AA6-B97B-4D9BD8788373Q38319987-C381C149-083C-4DAF-B3A0-3AEC6E1B169EQ41133980-1E603E9D-F327-4CB5-86A0-D706EA5D0DF8Q42181679-32A96DA2-473B-4460-85F5-517058031AD4Q44746809-4BB8A96B-50D9-489B-819A-9D6D1842F366Q45784223-95C1D860-F5D8-477D-839B-3897E888D1DEQ47656975-6B9A7106-8EE1-4A56-B86E-0A6116E65F8FQ48124777-47A6DC42-3B9D-4404-9787-39F197B359C3Q50547545-78D72F6C-C7A3-436F-BD7B-F69CE8801BA2Q51596707-7FA24186-AB4F-4B2A-B513-2B398EFFB919Q51837133-EFB90A30-1965-4B66-9495-2B9F9190441FQ58325168-1C6B37F6-E65F-44F0-AA8E-5AFECB172EE7
P2860
Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 August 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Evaluation of BRCA1 and BRCA2 ...... k of breast and ovarian cancer
@en
Evaluation of BRCA1 and BRCA2 ...... of breast and ovarian cancer.
@nl
type
label
Evaluation of BRCA1 and BRCA2 ...... k of breast and ovarian cancer
@en
Evaluation of BRCA1 and BRCA2 ...... of breast and ovarian cancer.
@nl
prefLabel
Evaluation of BRCA1 and BRCA2 ...... k of breast and ovarian cancer
@en
Evaluation of BRCA1 and BRCA2 ...... of breast and ovarian cancer.
@nl
P2093
P2860
P50
P356
P1476
Evaluation of BRCA1 and BRCA2 ...... k of breast and ovarian cancer
@en
P2093
Anne-Marie Moisan
Bartha-Maria Knoppers
Bernard Lespérance
Béatrice Godard
Carolle Samson
Claire Brousseau
David Goldgar
Francine Durocher
Gilles Leblanc
Hélène Malouin
P2860
P304
P356
10.1136/JMG.2006.044388
P407
P577
2006-08-11T00:00:00Z